Scientific Advisory Board

Dr. J. Victor Garcia

Dr. J. Victor Garcia is a Professor of Medicine in the Center for AIDS Research (CFAR), the Institute for Global Health & Infectious Diseases (IGHID), and the Division of Infectious Diseases in the Department of Medicine, all at the University of North Carolina at Chapel Hill. He is an Oliver Smithies Investigator and a Fellow of the American Academy of Microbiology. Throughout his career, Dr. Garcia has established himself as an expert in the development, implementation and use of humanized mice for biomedical research, particularly in the area of infectious disease. Dr. Garcia received a Bachelor of Science in Chemistry from the Instituto Tecnológico y de Estudios Superiores de Monterrey and a PhD in Chemistry from Georgetown University.

Dr. Andrew Goodman

Dr. Andrew Goodman is an Associate Professor of Microbial Pathogenesis and a member of the Microbial Sciences Institute at Yale University School of Medicine. For this work, Dr. Goodman has been recognized with the NIH Director's New Innovator Award, the Pew Scholars Fellowship, DuPont Young Professor Award, Burroughs Wellcome Fund Investigator Award, Howard Hughes Medical Institute Faculty Scholar Award, and the Presidential Early Career Award in Science and Engineering. Dr. Goodman's research is focused on understanding the mechanisms of interaction between members of the human gut microbiome and with the host. The Goodman lab combines microbial genetics, gnotobiotic animal models, and computational approaches to develop new technologies for studying the microbiome and to apply these approaches to uncover the causes and consequences of interpersonal microbiome variation. Dr. Goodman was trained in ecology and evolutionary biology at Princeton University and completed his PhD in microbiology at Harvard Medical School.

Dr. David Hill

Dr. David Hill has established a successful and extensive career leading the pharmacology departments of many major pharmaceutical companies, including a combined twenty years at Organon and Merck. Dr. Hill's therapeutic expertise includes neuroscience, pain, anesthesia, cardiometabolic disease, and oncology. During his career, Dr. Hill played a pivotal role in directing preclinical animal model programs of various sizes that resulted in many new approved therapeutics. Beyond his scientific expertise, Dr. Hill also brings a keen knowledge of harmonizing internal and outsourced resources to produce both sound scientific and business results. Dr. Hill earned a Bachelor of Science in Applied Biology from Hatfield Polytechnic and PhD in pharmacology from St. Thomas Hospital Medical School.